Wave Life Sciences WVE-007 Results Highlight Fat Loss

Wave Life Sciences disclosed on March 26, 2026, that its WVE-007 investigational drug produced significant reductions in visceral and total fat but only minimal weight change. The company said it will begin a Phase 2a multidose trial in the second quarter of 2026.

Six-Month Phase 1 INLIGHT Results

The INLIGHT Phase 1 trial tested a single ascending 240 mg dose of WVE-007 in 32 adults with an average body-mass index (BMI) of about 32 kg/m², randomized 3:1 versus placebo. After six months, the placebo-adjusted results showed a 14.3% reduction in visceral fat (p<0.05), 5.0% decline in total fat, 3.3% decrease in waist circumference, 0.9% drop in body weight, and a 2.0% increase in lean mass. The visceral fat-to-muscle ratio improved 16.5% from baseline, exceeding the 12.2% change reported in a semaglutide Phase 2 cohort with a higher average BMI of about 37 kg/m². Earlier three-month data showed a smaller visceral fat reduction of about 7.8% and modest changes in waist and weight.

Mechanism, Safety and Development Plans

WVE-007 is an investigational GalNAc-siRNA (small interfering RNA) using SpiNA chemistry to silence INHBE mRNA, aiming to trigger fat cell lipolysis while preserving muscle. Preclinical studies showed it shrinks fat cells, reduces inflammation and fibrosis in visceral fat, and improves insulin sensitivity. In mice, combining WVE-007 with semaglutide doubled weight loss and helped prevent weight regain.

Pharmacodynamic data revealed dose-dependent suppression of circulating Activin E sustained for at least seven months, with a maximum reduction of 88%. This extended effect supports potential once- or twice-yearly dosing.

Safety data from the single ascending dose portion showed WVE-007 was generally well tolerated up to 600 mg, with no discontinuations or severe treatment-emergent adverse events. Treatment-related adverse events were mild, and there were no significant changes in lipid profiles or liver-function tests.

Wave Life Sciences plans to start the Phase 2a multidose portion of INLIGHT in the second quarter of 2026. This trial will enroll patients with higher BMI (35–50 kg/m²) and comorbidities, assessing body composition and weight change three months after the first dose. The results will guide development for obesity, metabolic dysfunction–associated steatohepatitis (MASH), type 2 diabetes, and cardiovascular disease. The company expects greater effects in patients with higher baseline BMI and is considering adding GLP-1 therapies or post-incretin maintenance strategies. It noted that visceral fat reductions of roughly 5–10% have been linked to lower risks of MASH, type 2 diabetes, and cardiovascular outcomes. Additional six-month data from a 600 mg single-dose cohort are expected later in 2026.

Because the Phase 1 trial involved a single dose in participants with lower average BMI than typical late-stage obesity trials, the upcoming multidose study in heavier patients will be critical to determine if the body-composition improvements translate into meaningful weight loss.